Rtw Investments Adds $296M in CG Oncology, Inc. ($CGON)
RTW Investments has boosted its position in CGON by 247%, now holding 6.98 million shares.
Key Points
- RTW Investments increased its stake in CGON by 247%, adding 4.97 million shares to hold a total of 6.98 million shares valued at $416 million.
- CGON shares were trading at $59.56 with a market cap reflecting recent strong institutional interest.
- Analysts from Truist Securities and JP Morgan maintain a 'buy' rating for CGON with targets up to $100.
RTW Investments has made a significant move by boosting its stake in CGON, according to its latest Form 13F filing with the SEC. The firm increased its holdings by 247%, adding 4,972,681 shares, bringing its total to 6,984,808 shares. The value of this position is approximately $416 million as of the filing date.
What Changed in RTW Investments's CGON Position
RTW Investments previously held 2,012,127 shares of CGON. By adding 4,972,681 shares, it now owns 6,984,808 shares, a 247% increase. This substantial addition reflects a strong position in CGON, valued at about $416 million.
Other Institutional Activity in CGON
Other major funds have also been active in CGON. T. Rowe Price Investment Management significantly increased its holdings by 6,297,797 shares, now holding 6,720,389 shares valued at $454.8 million. Decheng Capital maintained its position with 6,371,669 shares worth $431.2 million. Wellington Management Group reduced its stake by 628,558 shares, holding 5,371,232 shares valued at $363.5 million. BlackRock added 220,938 shares, bringing its total to 5,064,180 shares valued at $342.7 million. Meanwhile, FMR LLC trimmed its holdings by 533,329 shares, now holding 3,764,844 shares valued at $254.8 million.
CGON Stock Snapshot
CGON shares recently traded at $59.56. The company has seen increased interest from institutional investors, reflecting its current market dynamics. The stock's performance is underpinned by positive analyst sentiment and a strong institutional presence.
Insider Buying and Selling at CG Oncology, Inc.
On June 4, 2026, several insiders were active in CGON transactions. Leonard Post sold 1,000 shares, while Christina Rossi, Victor Edward Jr. Tong, Susan Graf, Brian Guan-Chyun Liu, and James Mulay each purchased 9,354 shares. These transactions were not executed under a Rule 10b5-1 plan.
Analysts Set New Price Targets
Analysts remain optimistic about CGON's prospects. On May 14, 2026, Truist Securities reiterated its 'buy' rating with an $82 price target. JP Morgan and RBC Capital also maintained their 'buy' ratings, setting targets at $96 and $81, respectively. The consensus among analysts is a favorable outlook, with a mean price target reflecting confidence in CGON's future performance.
About CGON
CGON operates in a sector that involves [specific industry details]. The company is headquartered in [location], and its operations focus on [business focus]. Its leadership team is headed by [CEO name], guiding a workforce of [number] employees.
Bottom Line
RTW Investments' significant increase in its CGON holdings underscores a strong institutional interest in the company. This move reflects confidence in CGON's potential, as seen in both the substantial share increase and the positive analyst ratings. Remember, 13F filings are backward-looking and may not represent current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.